257 related articles for article (PubMed ID: 37523318)
1. Estimated discounts generated by Medicare drug negotiation in 2026.
Hernandez I; Gabriel N; Dickson S
J Manag Care Spec Pharm; 2023 Aug; 29(8):868-872. PubMed ID: 37523318
[No Abstract] [Full Text] [Related]
2. Drugs likely subject to Medicare negotiation, 2026-2028.
Dickson S; Hernandez I
J Manag Care Spec Pharm; 2023 Mar; 29(3):229-235. PubMed ID: 36840960
[No Abstract] [Full Text] [Related]
3. Examining Opportunities to Increase Savings From Medicare Price Negotiations.
Reitsma MB; Dusetzina SB; Ballreich JM; Trujillo AJ; Mello MM
JAMA Intern Med; 2023 Jun; 183(6):581-588. PubMed ID: 37067794
[TBL] [Abstract][Full Text] [Related]
4. Simulated Medicare Drug Price Negotiation Under the Inflation Reduction Act of 2022.
Rome BN; Nagar S; Egilman AC; Wang J; Feldman WB; Kesselheim AS
JAMA Health Forum; 2023 Jan; 4(1):e225218. PubMed ID: 36705916
[TBL] [Abstract][Full Text] [Related]
5. Price benchmarks of drugs selected for Medicare price negotiation and their therapeutic alternatives.
Hernandez I; Cousin EM; Wouters OJ; Gabriel N; Cameron T; Sullivan SD
J Manag Care Spec Pharm; 2024 Jun; ():1-11. PubMed ID: 38905356
[TBL] [Abstract][Full Text] [Related]
6. Nonfederal average manufacturer price to estimate savings generated by minimum discounts under the Inflation Reduction Act.
Hernandez I; Gabriel N; Dickson S
J Manag Care Spec Pharm; 2023 Nov; 29(11):1261-1263. PubMed ID: 37889864
[No Abstract] [Full Text] [Related]
7. Sociodemographic and spending characteristics of Medicare beneficiaries taking prescription drugs subject to price negotiations.
Odouard IC; Anderson GF; Alexander GC; Ballreich J
J Manag Care Spec Pharm; 2024 Mar; 30(3):269-278. PubMed ID: 38140901
[TBL] [Abstract][Full Text] [Related]
8. Estimated Changes in Manufacturer and Health Care Organization Revenue Following List Price Reductions for Hepatitis C Treatments.
Dickson S; Reynolds I
JAMA Netw Open; 2019 Jul; 2(7):e196541. PubMed ID: 31276176
[TBL] [Abstract][Full Text] [Related]
9. The Price-Quality Mismatch: Are Negotiated Prices for Total Joint Arthroplasty Associated With Hospital Quality in a Large California Health System?
Zhuang T; Shapiro LM; Baker LC; Kamal RN
Clin Orthop Relat Res; 2023 Jun; 481(6):1061-1068. PubMed ID: 36729581
[TBL] [Abstract][Full Text] [Related]
10. Estimated Savings From Using Added Therapeutic Benefit and Therapeutic Reference Pricing in United States Medicare Drug Price Negotiations.
DiStefano MJ; Levy JF; Odouard IC; Anderson GF
Value Health; 2023 Nov; 26(11):1618-1624. PubMed ID: 37689264
[TBL] [Abstract][Full Text] [Related]
11. Estimates of Medicaid and Non-Medicaid Net Prices of Top-Selling Brand-name Drugs Incorporating Best Price Rebates, 2015 to 2019.
Clemans-Cope L; Epstein M; Banthin J; Kesselheim AS; Hwang TJ
JAMA Health Forum; 2023 Jan; 4(1):e225012. PubMed ID: 36637815
[TBL] [Abstract][Full Text] [Related]
12. Role of Specialty Drugs in Rising Drug Prices for Medicare Part D.
Hayford TB
JAMA Health Forum; 2024 May; 5(5):e241188. PubMed ID: 38787543
[TBL] [Abstract][Full Text] [Related]
13. Assessment of Commercial and Mandatory Discounts in the Gross-to-Net Bubble for the Top Insulin Products From 2012 to 2019.
Dickson SR; Gabriel N; Gellad WF; Hernandez I
JAMA Netw Open; 2023 Jun; 6(6):e2318145. PubMed ID: 37314806
[TBL] [Abstract][Full Text] [Related]
14. Medicare price negotiation and pharmaceutical innovation following the Inflation Reduction Act.
Vogel M; Kakani P; Chandra A; Conti RM
Nat Biotechnol; 2024 Mar; 42(3):406-412. PubMed ID: 38297186
[TBL] [Abstract][Full Text] [Related]
15. Increasing Divergence in Drug Prices Between the United States and Germany After Implementation of Comparative Effectiveness Analysis and Collective Price Negotiations.
Berkemeier F; Whaley C; Robinson JC
J Manag Care Spec Pharm; 2019 Dec; 25(12):1310-1317. PubMed ID: 31778624
[TBL] [Abstract][Full Text] [Related]
16. Estimating Rebates and Other Discounts Received by Medicare Part D.
Feldman WB; Rome BN; Raimond VC; Gagne JJ; Kesselheim AS
JAMA Health Forum; 2021 Jun; 2(6):e210626. PubMed ID: 36218748
[TBL] [Abstract][Full Text] [Related]
17. Getting the Price Right: Lessons for Medicare Price Negotiation from Peer Countries.
Rand LZ; Kesselheim AS
Pharmacoeconomics; 2022 Dec; 40(12):1131-1142. PubMed ID: 36348153
[TBL] [Abstract][Full Text] [Related]
18. Cost of Exempting Sole Orphan Drugs From Medicare Negotiation.
Vogel M; Zhao O; Feldman WB; Chandra A; Kesselheim AS; Rome BN
JAMA Intern Med; 2024 Jan; 184(1):63-69. PubMed ID: 38010643
[TBL] [Abstract][Full Text] [Related]
19. Inflationary Rebates For Generic Drugs Sold Through Medicaid Saved Billions During 2017-20.
Rome BN; Patel AN; Kesselheim AS
Health Aff (Millwood); 2023 Jun; 42(6):770-778. PubMed ID: 37276474
[TBL] [Abstract][Full Text] [Related]
20. Changes in List Prices, Net Prices, and Discounts for Branded Drugs in the US, 2007-2018.
Hernandez I; San-Juan-Rodriguez A; Good CB; Gellad WF
JAMA; 2020 Mar; 323(9):854-862. PubMed ID: 32125403
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
